{{chembox
| Verifiedfields = changed
| verifiedrevid = 437141678
| ImageFile = Ebselen-2D-skeletal.png
| ImageSize = 200px
| ImageName = Skeletal formula of ebselen
| ImageFile1 = Ebselen-3D-balls.png
| ImageSize1 = 200px
| ImageFile2 = Ebselen-3D-vdW.png
| ImageSize2 = 200px
| ImageName1 = Ball-and-stick model of the ebselen molecule
| IUPACName = 2-Phenyl-1,2-benzoselenazol-3-one
| OtherNames=
|Section1={{Chembox Identifiers
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3082
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 40X2P7DPGH
| InChI = 1/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H
| InChIKey = DYEFUKCXAQOFHX-UHFFFAOYAZ
| SMILES1 = O=C1c3ccccc3[Se]N1c2ccccc2
| ChEBI_Ref = {{ebicite|changed|EBI}} 
| ChEBI = 77543
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 51085
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = DYEFUKCXAQOFHX-UHFFFAOYSA-N
| CASNo_Ref = {{cascite|correct|??}}
| CASNo= 60940-34-3
| PubChem=3194
| SMILES=C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2
  }}
|Section2={{Chembox Properties
| Formula=C<sub>13</sub>H<sub>9</sub>NOSe
| MolarMass=274.17666
| Appearance=
| Density=
| MeltingPt=
| BoilingPt=
| Solubility=
  }}
|Section3={{Chembox Hazards
| MainHazards=
| FlashPt=
| AutoignitionPt =
  }}
}}

'''Ebselen''' (also called '''PZ 51''', '''DR3305''', and '''SPI-1005'''), is a synthetic organoselenium drug molecule with anti-inflammatory, anti-oxidant and cytoprotective activity. It acts as a mimic of [[glutathione peroxidase]] and can also react with [[peroxynitrite]].<ref>{{cite journal |author=Schewe T |title=Molecular actions of ebselen--an antiinflammatory antioxidant |journal=Gen Pharmacol |volume=26 |issue=6 |pages=1153–69 |year=1995 |pmid=7590103 |doi=10.1016/0306-3623(95)00003-J}}</ref> It is being investigated as a possible treatment for [[reperfusion injury]] and [[stroke]],<ref>{{cite journal |vauthors=Parnham M, Sies H |title=Ebselen: prospective therapy for cerebral ischaemia |journal=Expert Opin Investig Drugs |volume=9 |issue=3 |pages=607–19 |year=2000 |pmid=11060699 |doi=10.1517/13543784.9.3.607}}</ref><ref>{{cite journal |vauthors=Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, Yasuhara H |title=Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group |url=http://stroke.ahajournals.org/cgi/content/full/29/1/12 |journal=Stroke |volume=29 |issue=1 |pages=12–7 |date=1 January 1998|pmid=9445321 |doi=10.1161/01.STR.29.1.12 }}</ref> [[hearing loss]] and [[tinnitus]],<ref>{{cite journal|title=Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase|journal=Hearing Research|volume=226|issue=1–2|pages=44–51|last1=Kil|first1=Jonathan|year=2007|last2=Pierce|first2=Carol|last3=Tran|pmid=17030476|first3=Huy|last4=Gu|first4=Rende|last5=Lynch|first5=Eric D|doi=10.1016/j.heares.2006.08.006}}</ref> and [[bipolar disorder]].<ref>{{Cite journal | last1 = Singh | first1 = N. | last2 = Halliday | first2 = A. C. | last3 = Thomas | first3 = J. M. | last4 = Kuznetsova | first4 = O. V. | last5 = Baldwin | first5 = R. | last6 = Woon | first6 = E. C. Y. | last7 = Aley | first7 = P. K. | last8 = Antoniadou | first8 = I. | last9 = Sharp | first9 = T. | last10 = Vasudevan | first10 = S. R. | last11 = Churchill | first11 = G. C. | title = A safe lithium mimetic for bipolar disorder | doi = 10.1038/ncomms2320 | journal = Nature Communications | volume = 4 | pages = 1332 | year = 2013 | pmid =  23299882| pmc =3605789 }}</ref><ref>{{cite web |url=http://www.ox.ac.uk/news/2013-01-08-new-drug-bipolar-disorder-may-offer-fewer-side-effects |title=New drug for bipolar disorder may offer fewer side effects |author=<!--Staff writer(s); no by-line.--> |date=2013-01-08 |work=[[University of Oxford]] Latest News |accessdate=12 January 2013}}</ref>

Additionally, ebselen may be effective against [[Clostridium difficile (bacteria)|''Clostridium difficile'']] infections.<ref>{{cite web | url = http://medicalxpress.com/news/2015-09-drug-deadly-difficile-bacteria-healthy.html | title = Drug disarms deadly C. difficile bacteria without destroying healthy gut flora | publisher = Medical Express}}</ref>

Ebselen is a potent scavenger of hydrogen peroxide as well as hydroperoxides including membrane bound phospholipid and cholesterylester hydroperoxides. Several ebselen [[structural analog|analogs]] have been shown to scavenge hydrogen peroxide in the presence of thiols.<ref>{{cite journal |vauthors=Satheeshkumar K, Mugesh G |title=Synthesis and Antioxidant Activity of Peptide-Based Ebselen Analogues. |journal=Chem. Eur. J. |volume=17 |issue=17 |pages=4849–57 |year=2011 |doi=10.1002/chem.201003417}}</ref>

== Synthesis ==
Generally, synthesis of the characteristic scaffold of ebselen, the benzoisoselenazolone ring system, can be achieved either through reaction of primary amines (RNH<sub>2</sub>) with 2-(chloroseleno)benzoyl chloride (Route I),<ref>{{Cite journal|last=Kamigata|first=Nobumasa|last2=Iizuka|first2=Hirokazu|last3=Izuoka|first3=Akira|last4=Kobayashi|first4=Michio|date=1986-01-01|title=Photochemical Reaction of 2-Aryl-1,2-benzisoselenazol-3(2H)-ones|url=https://www.jstage.jst.go.jp/article/bcsj1926/59/7/59_7_2179/_article|journal=Bulletin of the Chemical Society of Japan|volume=59|issue=7|pages=2179–2183|doi=10.1246/bcsj.59.2179}}</ref><ref>{{Cite journal|last=Elsherbini|first=Mohamed|last2=Hamama|first2=Wafaa S.|last3=Zoorob|first3=Hanafi H.|last4=Bhowmick|first4=Debasish|last5=Mugesh|first5=Govindasamy|last6=Wirth|first6=Thomas|date=2014-11-01|title=Synthesis and Antioxidant Activities of Novel Chiral Ebselen Analogues|url=http://onlinelibrary.wiley.com/doi/10.1002/hc.21164/abstract|journal=Heteroatom Chemistry|language=en|volume=25|issue=5|pages=320–325|doi=10.1002/hc.21164|issn=1098-1071}}</ref> by ''ortho''-lithiation of benzanilides followed by oxidative cyclization (Route II) mediated by cupric bromide (CuBr<sub>2</sub>),<ref>{{Cite journal|last=Engman|first=Lars|last2=Hallberg|first2=Anders|date=1989-06-01|title=Expedient synthesis of ebselen and related compounds|url=https://dx.doi.org/10.1021/jo00273a035|journal=The Journal of Organic Chemistry|volume=54|issue=12|pages=2964–2966|doi=10.1021/jo00273a035|issn=0022-3263}}</ref>  or through the efficient Cu-catalyzed selenation / heterocyclization of o-halobenzamides, a methodology developed by Kumar ''et al.''<ref>{{Cite journal|last=Balkrishna|first=Shah Jaimin|last2=Bhakuni|first2=Bhagat Singh|last3=Chopra|first3=Deepak|last4=Kumar|first4=Sangit|date=2010-12-03|title=Cu-Catalyzed Efficient Synthetic Methodology for Ebselen and Related Se−N Heterocycles|url=https://dx.doi.org/10.1021/ol102027j|journal=Organic Letters|volume=12|issue=23|pages=5394–5397|doi=10.1021/ol102027j|issn=1523-7060|pmid=21053969}}</ref> (Route III).

[[File:Ebselen_Routes.png|frameless|637x637px]]

==References==
{{reflist|2}}

[[Category:Organoselenium compounds]]